UNSPSC 51262908: Bopindolol

This classification denotes an adrenergic beta-antagonist with the molecular formula C23H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KT304VZO57, chemically known as 2-propanol, 1-((1,1-dimethylethyl)amino)-3-((2-methyl-1h-indol-4-yl)oxy)-, benzoate (ester), (+-)- but generally known as bopindolol, which bears US NIH Compound Identifier 44112. Bopindolol most often comes in base and malonate forms.

UNSPSC 51262908 Bopindolol is a Commodity code nominally covering a specific beta-blocker pharmaceutical, but the recent state and local opportunities tagged to this code do not reflect pharmaceutical inventory procurement aligned with the code's name. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to support community health initiatives, a procurement substantially outside the scope of a single branded pharmaceutical. Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 exploring vendor capacity for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, which addresses pharmacy benefit program structure and contracting models rather than specific drug procurement. The mismatch between the code's nominal scope and the actual work being solicited suggests this code sees limited relevant recent activity aligned to bopindolol or similar beta-blocker products under state and local procurement.

The two opportunities on record span different procurement mechanics and jurisdictional scales. Seminole County's IFB with a response deadline of July 26, 2023 (a date inconsistent with the June 2026 posting date in the source) targets a county health department with specific unit quantities and quarterly delivery cycles, while the Texas HHS RFI, posted April 3, 2026 with immediate response deadline, represents exploratory market intelligence at the state level focused on pharmacy benefit program architecture rather than product procurement. Geographic activity is limited to Florida and Texas based on these records, and both opportunities appear to address public health supply chains or benefit administration rather than pharmaceutical purchasing aligned with the code's stated commodity.